Center for Medical Research Methodology, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
Mol Med. 2011 May-Jun;17(5-6):378-90. doi: 10.2119/molmed.2011.00021. Epub 2011 Jan 25.
Both common forms of diabetes have an inflammatory pathogenesis in which immune and metabolic factors converge on interleukin-1β as a key mediator of insulin resistance and β-cell failure. In addition to improving insulin resistance and preventing β-cell inflammatory damage, there is evidence of genetic association between diabetes and histone deacetylases (HDACs); and HDAC inhibitors (HDACi) promote β-cell development, proliferation, differentiation and function and positively affect late diabetic microvascular complications. Here we review this evidence and propose that there is a strong rationale for preclinical studies and clinical trials with the aim of testing the utility of HDACi as a novel therapy for diabetes.
两种常见形式的糖尿病都具有炎症发病机制，其中免疫和代谢因素集中在白细胞介素-1β上，作为胰岛素抵抗和β细胞衰竭的关键介质。除了改善胰岛素抵抗和预防β细胞炎症损伤外，还有证据表明糖尿病与组蛋白去乙酰化酶（HDAC）之间存在遗传关联；并且 HDAC 抑制剂（HDACi）可促进β细胞的发育、增殖、分化和功能，并对糖尿病的晚期微血管并发症产生积极影响。在这里，我们回顾了这方面的证据，并提出了一个强有力的理由，即需要进行临床前研究和临床试验，以测试 HDACi 作为治疗糖尿病的新疗法的效用。
